Loading company…
Shennon Biotechnologies develops immunotherapies for solid tumors and autoimmune diseases.
Shennon Biotechnologies uses a single-cell platform to profile immune cells and identify targets for immunotherapy development. Founded in 2021 by CEO Li Sun, the company is based in San Francisco, US. In September 2026, it raised USD 12 million in venture funding from Atypical Ventures, Future Ventures, NextGen Venture Partners, Samos Investments, Saras Capital, AV8 Ventures, DCVC, and Foundation Capital to advance cancer programs and its T-cell engager platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in